Background
==========

Activation of the nitric oxide -- soluble guanylate cyclase -- cyclic guanosine monophosphate (NO-sGC-cGMP) pathway can induce potent cardioprotection-like effects against ischemia-reperfusion injury. We investigated the effects of pharmacological preconditioning with cinaciguat (BAY 58-2667), a novel sGC-activator on myocardial and coronary vascular function during reperfusion in a canine model of cardioplegic arrest and extracorporal circulation.

Materials and methods
=====================

Vehicle- (control group, n = 6) and cinaciguat-pretreated (8.33 μg/h iv. for 30 min; n = 7 low-dose treatment group and 25 μg/h iv. for 30 min; n = 6 high-dose treatment group) anesthetized dogs underwent cardiopulmonary bypass with 60 min of hypothermic cardiac arrest. Left and right ventricular end-systolic pressure volume relationship (ESPVR) was measured by a combined pressure-volume conductance catheter at baseline and after 60 min of reperfusion. Left anterior descending coronary blood flow, vasodilatation to acetylcholine and myocardial level of adenosine triphosphate were determined.

Results
=======

Compared to control, pharmacological preconditioning with cinaciguat (25 μg/h) led to significantly higher myocardial adenosine triphosphate content, to a better recovery of left and right ventricular contractility (Δ slope of left ventricular ESPVR given as percent of baseline: 102.4 ± 19.1 vs. 56.0 ± 7.1%, p \< 0.05) and to a higher coronary blood flow (49.6 ± 3.5 vs. 28.0 ± 3.9 ml/min, p \< 0.05). Endothelium-dependent vasodilatory responses to acetylcholine were improved in the treatment groups.

Conclusion
==========

Preconditioning with cinaciguat improves myocardial and endothelial function after cardiopulmonary bypass with hypothermic cardiac arrest. The observed protective effects imply that pharmacological sGC-activation could be a novel therapeutic option in the protection against ischemia-reperfusion injury in cardiac surgery.
